Astec Lifesciences

April 13 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• ASTEC LIFESCIENCES LTD - NADIR GODREJ RETIRES FROM CHAIRMANSHIP

Source text: ID:nBSE6llm5n

Further company coverage: ASTE.NS

(([email protected];))

Sept 29 (Reuters) - Godrej Agrovet Ltd GODE.NS:

• ADMINISTRATIVE WARNING LETTER FROM SECURITIES AND EXCHANGE BOARD OF INDIA

• LETTER FOR VIOLATION OF ACQUISITION PROVISIONS IN MATTER OF ASTEC LIFESCIENCES

Source text: ID:nBSE9pq3Bp

Further company coverage: GODE.NSASTE.NS

(([email protected];))

June 30 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• RIGHTS ISSUE PRICE AT 890 RUPEES PER SHARE

Source text: ID:nBSE6K9wF3

Further company coverage: ASTE.NS

(([email protected];;))

June 24 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• ASTEC LIFESCIENCES LTD - APPROVES RIGHTS ISSUE UP TO 2.50 BILLION RUPEES

Source text: ID:nBSE1Q23VN

Further company coverage: ASTE.NS

(([email protected];;))

June 19 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• TO CONSIDER FUND RAISING

Source text: ID:nnAZN403WQT

Further company coverage: ASTE.NS

(([email protected];;))

April 23 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• ASTEC LIFESCIENCES LTD MARCH-QUARTER CONSOL NET LOSS 160.9 MILLION RUPEES

• ASTEC LIFESCIENCES LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.2 BILLION RUPEES

Further company coverage: ASTE.NS

(([email protected];;))

July 29 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• ASTEC LIFESCIENCES - MUGDHA AMOL KHARE NAMED AS CFO

Further company coverage: ASTE.NS

(([email protected];))

May 2 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• ASTEC LIFESCIENCES LTD - RESIGNATION OF K. SURYANARAYAN FROM POSITION OF CFO

• INDIA'S ASTEC LIFESCIENCES MAR-QUARTER CONSOL NET LOSS 9.7 MILLION RUPEES VERSUS LOSS 49.8 MILLION RUPEES

• ASTEC LIFESCIENCES MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.54 BILLION RUPEES VERSUS 1.27 BILLION RUPEES

Source text for Eikon: ID:nBSE4frWW3

Further company coverage: ASTE.NS

(([email protected];))

Corrects to "agrees" from "agree" in headline

BENGALURU, May 1 (Reuters) - India's Godrej family has decided to restructure its shareholding in the conglomerate to operate as two entities, Godrej Enterprises and Godrej Industries, according to a filing late on Tuesday.

The realignment will be implemented after the relevant regulatory approvals have been obtained, after which the two companies will continue to use the Godrej brand, it added.

Godrej Enterprises Group (GEG) will be headed by 75-year-old Jamshyd Godrej as chairperson and managing director and his niece Nyrika Holkar as executive director.

GEG operates across aerospace, aviation, defence and liquid engines among others.

Jamshyd Godrej was earlier serving as managing director and chairman of Godrej & Boyce, the privately held company, founded in 1897.

Nadir Godrej, 73, will serve as chairperson of Godrej Industries Group (GIG), which operates via listed companies including Godrej Industries GODI.NS, Godrej Consumer Products GOCP.NS, Godrej Properties GODR.NS, Godrej Agrovet GODE.NS and Astec Lifesciences ASTE.NS. GIG will be controlled by Nadir's brother Adi Godrej and their immediate family.

82-year-old Adi Godrej stepped down as chairman of Godrej Industries in August 2021, handing over the reign to his brother, Nadir Godrej.

Adi Godrej's son Pirojsha Godrej will be named chairperson of GIG, succeeding Nadir Godrej in August 2026.

(Reporting by Ashna Teresa Britto in Bengaluru; Editing by Eileen Soreng)

(([email protected];))

** Shares of India's Astec LifeSciences ASTE.NS down 4.2% to its lowest levels since Dec 2020

** Agricultural chemicals maker posted Q3 consol net loss of 243.3 mln rupees vs 8.4 mln rupees profit; rev falls by over 50%

** Co on track for fifth consecutive month of decline, longest monthly losing streak since late 2012-early 2013

** About 56,000 shares changed hands by 12:52 p.m. IST, nearly 1.5x 30-day avg

** Stock fell over 17% in Q3 FY2024, and ended CY2023 with a loss of 37.5%

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

** Indian fertilizer and agro-chemicals companies will likely face challenges for two more quarters on destocking by customers, Kotak Institutional Equities analysts said

** Add volume growth will remain under pressure until (and including) Q1 calendar year 2024 on a yoy basis due to destocking

** Outlook for the winter-sown crop season is somewhat challenging in India, especially in the south, due to lower water levels - brokerage

** Says recovery after Q1 CY2024 is seen only as modest, and the recent softness in corn prices is a worry in terms of end-demand for CY2024

** Ten out of 20 companies in Kotak's coverage universe, including Best Agrolife BESA.NS, Bharat Rasayan BRSN.NS, Coromandel CORF.NS, India Pesticides IDIP.NS, Meghmani Organics MEGH.NS, Sumitomo SUMH.NS and UPL UPLL.NS posted fall in core earnings and revenue in Q2 vs year ago

** Two cos, Astec LifeSciences ASTE.NS and Sharda Cropchem SHCR.NS, reported losses from yr ago profit

(Reporting by Nallur Sethuraman in Bengaluru)

(([email protected]; (+91 8061822737); Reuters Messaging: [email protected]))

Oct 27 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• INDIA'S ASTEC LIFESCIENCES LTD SEPT-QUARTER CONSOL NET LOSS 134.3 MILLION RUPEES VERSUS PROFIT 183.1 MILLION RUPEES

• ASTEC LIFESCIENCES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.11 BILLION RUPEES VERSUS 2 BILLION RUPEES

• ASTEC LIFESCIENCES LTD - APPROVAL FOR FURTHER ISSUANCE OF NON-CONVERTIBLE DEBENTURES UPTO AN ADDITIONAL AMOUNT OF 1 BILLION RUPEES

Source text for Eikon: ID:nBSE2rWX3J

Further company coverage: ASTE.NS

(([email protected];))

July 27 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• JUNE-QUARTER CONSOL NET LOSS 81.9 MILLION RUPEES VERSUS PROFIT 114 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.43 BILLION RUPEES VERSUS 1.84 BILLION RUPEES

Source text for Eikon: ID:nNSE3BHCSC

Further company coverage: ASTE.NS

(([email protected];))

** Shares of Astec LifeSciences Ltd ASTE.NS fall as much as 10.4% to 1,211.55 rupees, their lowest since March 29

** Agricultural chemicals maker reports consol net loss in March qtr at 49.8 mln rupees ($608,824.28) compared with a profit of 430.5 mln rupees a year earlier

** Co says subdued demand and subsequent correction in prices of key active ingredients led to drop in volumes along with lower realisations, affecting profitability

** Rev from ops fell 53.3% to 1.27 bln rupees

** Co's board appointed K. Suryanarayan as CFO

** Stock trading below its 50-, 100-, and 200-day moving averages

** Moving Average Convergence Divergence (MACD) line falls below the signal line, suggesting bearish bias

** Shares post their sharpest intraday pct loss since March 28

** More than 79,260 shares change hands by 10:05 a.m. IST, 1.3x the 30-day avg

** Stock down 22.8% so far this year, up to last close

($1 = 81.7970 Indian rupees)

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

May 2 (Reuters) - Astec Lifesciences Ltd ASTE.NS:

• INDIA'S ASTEC LIFESCIENCES LTD MAR-QUARTER CONSOL NET LOSS 49.8 MILLION RUPEES VERSUS PROFIT 430.5 MILLION RUPEES

• ASTEC LIFESCIENCES LTD MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.27 BILLION RUPEES VERSUS 2.72 BILLION RUPEES

• RECOMMENDED FINAL DIVIDEND OF 1.50 RUPEES PER SHARE

• MADHUR GUNDECHA RESIGNS AS CFO

• APPOINTS K. SURYANARAYAN AS CFO

Source text for Eikon: ID:nNSE751dxR

Further company coverage: ASTE.NS

(([email protected];))